The latest on breast cancer treatments: A chemotherapy breakthrough

The latest on breast cancer treatments: A chemotherapy breakthrough

A study published in the New England Journal of Medicine finds that a significant number of women with early-stage breast cancer may not require chemotherapy-which could potentially be a huge deal for tens of thousands of patients at the edges of the disease.

The research is the largest ever performed breast cancer therapy, and The outcomes are predicted to save around 70,000 patients per year from the US and a lot more elsewhere the ordeal and cost of those medications.

The study, led by the Albert Einstein Cancer Center in NY, is a rare cancer breakthrough as it can save money and instantly change practice.

"The results of PREOPANC trial certainly strengthens the argument for it", said Chang. Without the stamp money, the study may never have been done, he said.

The results of the study were presented on Sunday in Chicago at the American Society of Clinical Oncology meeting.

The trial was supported by the National Cancer Institute (NCI), part of the National Institutes of Health, and designed and led by the ECOG-ACRIN Cancer Research Group. When chemo is used now, it's sometimes for shorter periods or lower doses than it once was.

Rachel Rawson, from the charity Breast Cancer Care, said: "Every day, women with certain types of breast cancer face the awful dilemma of whether or not to have the treatment, without hard facts about the benefit for them".

According to Dr. Schmidt, "By looking at different genes in the breast cancer, the oncotype test can predict if women are low risk, intermediate risk, or high risk or recurrence and what their benefit or lack thereof of chemotherapy might be".

More news: Rajinikanth fans celebrate Kaala release
More news: A Hockey Nomad May Find a Permanent Home on the Stanley Cup
More news: Aston Villa Avert Threat Of Administration Following Unpaid Tax Bill

The usual treatment is surgery followed by years of a hormone-blocking drug. Doctors know that most don't need it, but evidence is thin on who can forgo it.

The analysis gave 10,273 patients an evaluation Named Oncotype DX, which utilizes a Biopsy sample to assess the action of genes involved with cell growth and response to hormone treatment, to gauge the risk that a cancer may recur.

About 17 percent of women had high-risk scores and were advised to have chemo.

The new results demonstrate that chemotherapy is not beneficial for most women in the intermediate-risk group.

After nine years, 94 percent of both groups were still alive, and about 84 percent were alive without signs of cancer, so adding chemo made no difference. In contrast, for patients with a low recurrence score (0-10), the benefits of chemotherapy are unlikely to outweigh the risks and toxicity.

One of the toughest decisions a woman with breast cancer will face is whether or not to undergo chemotherapy.

"We're getting to be able to personalize treatment now". Ray Lin, Scripps Medical Director of Radiation Oncology, to discuss the groundbreaking study. The money was used to pay for the gene test, which costs more than $4,000 per person.